Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Video & Webinars
Hematology
26th June 2015
ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain…
Hematology
26th June 2015
Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust…
Hematology
26th June 2015
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…
Oncology
26th June 2015
Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…
Oncology
26th June 2015
Phase 2 MMY2002 trial of daratumumab in myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…
Oncology
26th June 2015
Results of the phase 3 ELOQUENT-2 trial
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…
Oncology
26th June 2015
Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…
Oncology
26th June 2015
Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
Loading posts...
« Previous
1
…
87
88
89
90
91
…
98
Next »